Oxford Cannabinoid Technologies Holds PLC announced the formation of its scientific advisory board (SAB) to provide “scientific guidance on the company’s strategy and overall approach to clinical trials”.
The initial focus will be on the design of the pharmaceutical company’s upcoming phase 1 clinical trials for its cannabinoid medicines OCT130401 and OCT461201, according to a statement.
As well as that, the SAB will help shape the company’s approach beyond phase 1 trials and into phase 2 trials in patients affected by debilitating pain conditions.
Making up the board initially will be Professor Robert Dworkin, Professor Anthony Dickenson and Doctor Giorgio Lambru.
Professor Dworkin has been a consultant to the London-listed company since November 2021 and is a professor at the University of Rochester in New York.
Dworkin is also a director at a public-private partnership firm with the US Food and Drug Administration (FDA), the statement added.
Doctor Lambru has been consulting the company since February this year, and is a consultant neurologist, as well be an honorary senior lecturer at King’s College London.
He specialises in headaches and facial pain conditions and has authored scientific publications on these conditions.
Professor Dickenson has been consulting the company for a year and is a professor of neuropharmacology at University College, London.
His focus of research has been on understanding pain, and he is honorary member of the British Pain Society as well as being involved in several other advisory boards.
"Our research ethos is to develop breakthrough therapies for debilitating pain conditions with significant as yet unmet medical needs,” said chief scientific officer doctor Valentino Parravicini.